These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2879302)

  • 21. Amygdaloid D1 receptors are not linked to stimulation of adenylate cyclase.
    Leonard SK; Anderson CM; Lachowicz JE; Schulz DW; Kilts CD; Mailman RB
    Synapse; 2003 Dec; 50(4):320-33. PubMed ID: 14556237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
    Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
    J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential involvement of cyclase- versus non-cyclase-coupled D1-like dopamine receptors in orofacial movement topography in mice: studies with SKF 83822.
    Makihara Y; Okuda Y; Kawada C; Matsumoto M; Waddington JL; Koshikawa N; Tomiyama K
    Neurosci Lett; 2007 Mar; 415(1):6-10. PubMed ID: 17234342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine-sensitive adenylyl cyclase: a receptor mechanism for dopamine.
    Kebabian JW
    Adv Biochem Psychopharmacol; 1978; 19():131-54. PubMed ID: 29445
    [No Abstract]   [Full Text] [Related]  

  • 26. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo.
    Saller CF; Salama AI
    J Pharmacol Exp Ther; 1986 Mar; 236(3):714-20. PubMed ID: 3005552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.
    Spano PF; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1978; 19():155-65. PubMed ID: 358777
    [No Abstract]   [Full Text] [Related]  

  • 30. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanism for selectively inhibiting the activation of cyclic nucleotide phosphodiesterase and adenylate cyclase by antipsychotic agents.
    Weiss B; Levin RM
    Adv Cyclic Nucleotide Res; 1978; 9():285-303. PubMed ID: 27079
    [No Abstract]   [Full Text] [Related]  

  • 32. [Dopaminergic receptors, multiple targets for neuroleptics].
    Martres MP; Sokoloff P; Giros B; Bouthenet ML; Pilon C; Lannfelt L; Schwartz JC
    Ann Med Psychol (Paris); 1992; 150(2-3):119-23. PubMed ID: 1364189
    [No Abstract]   [Full Text] [Related]  

  • 33. The window of vulnerability in the ontogeny of the dopamine receptor.
    Miller JC; Friedhoff AJ
    Psychopharmacol Bull; 1985; 21(3):683-5. PubMed ID: 2863851
    [No Abstract]   [Full Text] [Related]  

  • 34. Neuroleptic CNS effects: acute and chronic studies.
    Bunney BS
    Psychopharmacol Bull; 1979 Jan; 15(1):57-8. PubMed ID: 33410
    [No Abstract]   [Full Text] [Related]  

  • 35. [Psychotropic drugs and adenylate cyclase (author's transl)].
    Honda F
    Tanpakushitsu Kakusan Koso; 1977; 22(6):822-6. PubMed ID: 22102
    [No Abstract]   [Full Text] [Related]  

  • 36. 6-(Phenylthio)-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines, a novel class of dopamine receptor antagonists and neuroleptics.
    Kaiser C; Ali FE; Bondinell WE; Brenner M; Holden KG; Ku TW; Oh HJ; Ross ST; Yim NC; Zirkle CL; Hahn RA; Sarau HM; Setler PE; Wardell JR
    J Med Chem; 1980 Sep; 23(9):975-6. PubMed ID: 6106062
    [No Abstract]   [Full Text] [Related]  

  • 37. 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs.
    Abbott A
    Trends Pharmacol Sci; 1990 Feb; 11(2):49-51. PubMed ID: 1969187
    [No Abstract]   [Full Text] [Related]  

  • 38. Multiple dopamine receptors. Proceedings of a workshop at the Ninth Society for Neuroscience Annual Meeting, Atlanta, Georgia, November 1979.
    Commun Psychopharmacol; 1979; 3(6):383-470. PubMed ID: 44692
    [No Abstract]   [Full Text] [Related]  

  • 39. Dopamine receptor diversity: molecular and pharmacological perspectives.
    Hartman DS; Civelli O
    Prog Drug Res; 1997; 48():173-94. PubMed ID: 9204687
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopamine receptor signaling and current and future antipsychotic drugs.
    Boyd KN; Mailman RB
    Handb Exp Pharmacol; 2012; (212):53-86. PubMed ID: 23129328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.